Takeda Pharmaceutical (TAK) Cash & Equivalents (2017 - 2026)

Takeda Pharmaceutical's Cash & Equivalents history runs 10 years deep, the most recent figure standing at $3.8 billion for Q1 2026.

• On a quarterly basis, Cash & Equivalents rose 50.32% year-over-year to $3.8 billion in Q1 2026; TTM through Mar 2026 was $3.8 billion, a 50.32% increase from a year earlier, with the FY2026 full-year figure at $4.0 billion, up 56.36% from the prior year.
• Cash & Equivalents fell to $3.8 billion in Q1 2026 per TAK's latest filing, from $4.3 billion in the prior quarter.
• Across five years, Cash & Equivalents topped out at $7.3 billion in Q1 2022 and bottomed at $2.0 billion in Q4 2023.
• The 5-year median for Cash & Equivalents is $4.0 billion (2023), against an average of $4.0 billion.
• Across the five-year window, Cash & Equivalents plunged 61.89% in 2023 and jumped 161.49% in 2024, its largest moves.
• Year by year, Cash & Equivalents stood at $4.8 billion in 2022, then sank by 59.77% to $2.0 billion in 2023, then jumped by 66.61% to $3.3 billion in 2024, then soared by 30.94% to $4.3 billion in 2025, then dropped by 10.84% to $3.8 billion in 2026.
• Per Business Quant, the three latest TAK Cash & Equivalents figures stand at $3.8 billion (Q1 2026), $4.3 billion (Q4 2025), and $4.6 billion (Q3 2025).